Autopsy report · NCT00760461

Domperidone in Refractory Gastroparesis

“Enrolled subjects were unable to receive drug from dispensing pharmacy.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 9 months before it stopped.
• 44 participants enrolled.
• Results were posted on the registry 6 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Yale University

Sponsor type

University, hospital or other

Conditions

Gastroparesis

Interventions

Domperidone

Participants

44

Sites

1

Countries

United States

Trials that died the same way

• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (69% match in meaning)
• The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia
  “We were unable to enroll eligible subjects for the study.” (66% match in meaning)
• Comparison of Three Approaches of Electrode Placement to Detect Changes in Motor Evoked Potentials During Spine Surgery
  “Unable to enroll patients.” (63% match in meaning)
• Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
  “Manufacturer discontinued drug before any participants could be enrolled.” (63% match in meaning)
• Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients
  “Unable to enroll and study intended patient population.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.